Analyst Price Target is $21.00
▲ +1,938.83% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for PAVmed in the last 3 months. The average price target is $21.00, with a high forecast of $21.00 and a low forecast of $21.00. The average price target represents a 1,938.83% upside from the last price of $1.03.
Current Consensus is
Strong Buy
The current consensus among 2 contributing investment analysts is to buy (strong buy) stock in PAVmed. This rating has held steady since July 2024, when it changed from a Buy consensus rating.
PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Read More
